Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Sympos
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| Neurocrine Biosciences, Inc. (NASDAQ: NBIX) | Delayed: 143.29 +1.98 (1.40%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $141.31 | 52 Week High | $58.46 | |||
| Open | $141.62 | 52 Week Low | $31.25 | |||
| Day High | $143.83 | P/E | N/A | |||
| Day Low | $140.75 | EPS | $-0.69 | |||
| Volume | 1,244,561 | |||||
